Is Lumeria profitable or generating revenue in 2026?

No. Lumeria is a pre-revenue, 3-person startup in the YC Summer 2026 batch, as of July 25, 2026. Its Berkeley profile describes only 'months of customer discovery,' with no disclosed paying customers, revenue figures, or named clients found in any source as of July 2, 2026.

Could AI replace what Lumeria is building?

Possibly. Perfect Corp already claims 95%+ test-retest reliability and 15-concern detection from a standard phone camera with no hardware, as of July 10, 2026 (vendor-claimed). If accurate, it undercuts the need for Lumeria's proprietary Lumoscope multispectral hardware, which has no independent clinical validation yet.

Who is Lumeria's biggest competitor?

Perfect Corp is the most direct threat: it powers AI skin analysis for Estee Lauder, Clinique, Sephora and 600+ retailers using only phone cameras (vendor-claimed, July 2026). VISIA/Canfield is the clinical incumbent, priced $7,000 to $20,000 per device, but serves med-spas rather than consumers.

Who owns Lumeria and has it raised funding?

Lumeria is privately owned by its two co-founders, Anthea Guo and Maryanne Alhallak, both with UC Berkeley backgrounds. It is part of Y Combinator's Summer 2026 batch, which typically involves a small YC investment, but no specific check size, valuation, or outside investors were found as of July 2026.

What does Lumeria's Lumoscope device actually do?

The Lumoscope is a proprietary phone-camera adapter using polarized light and UV fluorescence imaging plus AI to analyze skin, paired with an AI chatbot called Lumi that gives routines and an ingredient decoder. Per its own site, it is positioned as 'insight and monitoring, not diagnosis,' as of July 2026.

Does Lumeria have any regulatory or clinical validation for its skin-scanning claims?

No third-party clinical validation of Lumoscope's multispectral advantage has been found as of July 2, 2026; all claims originate from the company's own site and founder interviews. Lumeria explicitly disclaims diagnostic intent, framing the product as monitoring only, not a medical device.

YC Summer 2026 · United States

Lumeria

Early-stage startup building a phone-camera UV/polarized-light adapter for skin tracking.

Protection under test

Assessed 27 July 2026 · Evidence as of 27 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 27 July 2026 · Checkable from 2026-2027 · Every call on the record Checkpoint: First Lumoscope hardware shipment and early retention data test the core claim

The call

Lumeria is betting that UV and polarized light data beats a plain phone camera, a claim nobody outside the company has independently confirmed yet.

Lumeria sells a wearable device that uses special light and sensors to scan your skin for problems like sun damage and early signs of skin cancer, betting that its hardware captures details that a smartphone camera and artificial intelligence cannot match. A competing company called Perfect Corp is already doing similar skin analysis using just phone cameras and AI software, has clinical studies backing up its accuracy, and is selling through hundreds of retailers without any special hardware, which directly challenges Lumeria's core advantage. The critical question: if Perfect Corp or another camera-only competitor proves their phone-based approach works just as well as Lumeria's device on the specific skin conditions Lumeria is focused on, Lumeria's reason to exist disappears.

Why

AI pressure: Perfect Corp. Perfect Corp already does camera-only skin analysis with clinical validation claims and no extra hardware needed. Could AI do the core job? Yes, likely.

Bigger players: Perfect Corp. Perfect Corp sits inside Estee Lauder, Clinique, and 600+ retailers, giving it distribution Lumeria does not have. Could a giant copy it? Yes, easily.

What protects it. A physical adapter that captures UV fluorescence and polarized light data a plain phone camera cannot see, if that signal proves clinically meaningful.

What would change this call

Perfect Corp announces or ships a hardware attachment for UV or multispectral skin capture. Would close the exact gap Lumeria's hardware differentiation depends on.
Lumeria ships its first Lumoscope hardware units and publishes retention or pricing data. Tests whether consumers pay for hardware over free camera-based apps.
Independent (non-Perfect Corp funded) clinical study compares UV/multispectral imaging to phone-camera AI on same skin conditions. Would confirm or kill Lumeria's core claim that hardware sensing beats camera AI.

Key numbers

3 employees as of Jul 2026 (2026-07-25)
Perfect Corp claims 95%+ reliability, 15 concerns detected (2026-07-10)
VISIA clinical multispectral systems cost $7,000 to $20,000 (2026-05-27)

Named risks

Core hardware differentiation (multispectral/UV) unvalidated by any independent clinical study. Severity: high
Perfect Corp and other camera-only AI platforms rapidly closing the capability gap with no hardware needed. Severity: high
Extremely early stage with only 3 employees and no disclosed revenue or funding amount. Severity: high
Potential future FDA/regulatory scrutiny if monitoring claims shift toward diagnostic framing. Severity: medium
No disclosed pricing model; consumer willingness to pay for hardware plus subscription unproven. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Perfect Corp	losing to	Claims 95%+ accuracy, 15-concern detection via phone camera alone, no hardware, as of 2026-07-10 (vendor-claimed)
VISIA/Canfield Scientific	contesting	Clinical incumbent priced $7,000 to $20,000, fights channel not consumer wedge, as of 2026-05-27
Miiskin	contesting	Direct peer app for longitudinal mole and lesion photo-tracking, noted 2026-07-09
SkinVision	contesting	Consumer app for AI lesion risk screening, functional peer as of 2026-07-12
Clinikally	contesting	YC-backed AI dermatology copilot and telemedicine platform, direct category peer

Questions people ask

Is Lumeria profitable or generating revenue in 2026?: No. Lumeria is a pre-revenue, 3-person startup in the YC Summer 2026 batch, as of July 25, 2026. Its Berkeley profile describes only 'months of customer discovery,' with no disclosed paying customers, revenue figures, or named clients found in any source as of July 2, 2026.
Could AI replace what Lumeria is building?: Possibly. Perfect Corp already claims 95%+ test-retest reliability and 15-concern detection from a standard phone camera with no hardware, as of July 10, 2026 (vendor-claimed). If accurate, it undercuts the need for Lumeria's proprietary Lumoscope multispectral hardware, which has no independent clinical validation yet.
Who is Lumeria's biggest competitor?: Perfect Corp is the most direct threat: it powers AI skin analysis for Estee Lauder, Clinique, Sephora and 600+ retailers using only phone cameras (vendor-claimed, July 2026). VISIA/Canfield is the clinical incumbent, priced $7,000 to $20,000 per device, but serves med-spas rather than consumers.
Who owns Lumeria and has it raised funding?: Lumeria is privately owned by its two co-founders, Anthea Guo and Maryanne Alhallak, both with UC Berkeley backgrounds. It is part of Y Combinator's Summer 2026 batch, which typically involves a small YC investment, but no specific check size, valuation, or outside investors were found as of July 2026.
What does Lumeria's Lumoscope device actually do?: The Lumoscope is a proprietary phone-camera adapter using polarized light and UV fluorescence imaging plus AI to analyze skin, paired with an AI chatbot called Lumi that gives routines and an ingredient decoder. Per its own site, it is positioned as 'insight and monitoring, not diagnosis,' as of July 2026.
Does Lumeria have any regulatory or clinical validation for its skin-scanning claims?: No third-party clinical validation of Lumoscope's multispectral advantage has been found as of July 2, 2026; all claims originate from the company's own site and founder interviews. Lumeria explicitly disclaims diagnostic intent, framing the product as monitoring only, not a medical device.

Timeline

2026-07-25YC directory lists Lumeria as Active with 3 employees
2026-07-10Perfect Corp publicizes 95%+ reliability, 15-concern camera-only skin AI
2026-07-09Perfect Corp cites Wake Forest clinical validation study (vendor-claimed)
2026-07-02Berkeley SCET profiles Lumeria founders and Lumoscope device
2026-07-01Perfect Corp claims embedding with Estee Lauder, Sephora, 600+ retailers
2026-06-01Oura publishes Oura Ring 5 development update
2026-05-27VISIA/Canfield priced at $7,000 to $20,000 per device, per market roundup
2026Lumeria founded and joins YC Summer 2026 (S26) batch

Revision history

27 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Prized Truffle Daqstra